GB2478072A — THC and CBD for use in the treatment of brain tumours
Assigned to GW Pharma Ltd · Expires 2011-08-24 · 15y expired
What this patent protects
A combination of cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). for use in the treatment of a brain tumour, the compounds being in a ratio of the compounds are in the ratio of 5:1 to 1:5. The brain tumour may be a glioma/glioblastoma. The cannabinoids may be prese…
USPTO Abstract
A combination of cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). for use in the treatment of a brain tumour, the compounds being in a ratio of the compounds are in the ratio of 5:1 to 1:5. The brain tumour may be a glioma/glioblastoma. The cannabinoids may be present as plant extracts and may be administered separately, sequentially or simultaneously.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.